|
Volumn 3, Issue 2, 2001, Pages 65-70
|
A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
GLYCOPROTEIN;
PROSTATE SPECIFIC ANTIGEN;
RECOMBINANT HUMAN MONOCLONAL ANTIBODY VASCULOTROPIN ANTIBODY;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
VASCULOTROPIN ANTIBODY;
ADULT;
AGED;
ANGIOGENESIS;
ARTICLE;
ASTHENIA;
CANCER GROWTH;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
HYPONATREMIA;
MALE;
METASTASIS;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CARCINOMA;
TREATMENT OUTCOME;
TREATMENT PLANNING;
|
EID: 0035718890
PISSN: 10955100
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1525-1411.2001.32007.x Document Type: Article |
Times cited : (69)
|
References (20)
|